Artemis Medicare Services Ltd (ARTEMISMED) is currently trading at 301.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Artemis Medicare Services Limited operates multi-specialty and super-specialty hospitals, led by its 700-bed Gurugram flagship, the newly commissioned 300-plus-bed Raipur hospital, Mauritius facilities, home care services, and specialty healthcare platforms. Its clinical network spans more than 40 specialties and 14 Centres of Excellence, with particular strength in oncology, neurosciences, orthopaedics, cardiac care, transplants and critical care. Gurugram delivered the clearest operating aha: Q2 FY27 occupancy rose to 68.1%, inpatient volumes increased 12.0% year on year, ARPOB reached INR 86,631, and EBITDA margin expanded to 23.8%. The combination of stronger volumes, higher realisations and lower average length of stay indicates improving asset utilisation without relying solely on price increases. Artemis Medicare Services Limited is transitioning from a single flagship-led model toward a multi-city platform. Raipur began operations in July 2026, South Delhi is planned under a 30-year operating agreement, Mauritius has expanded to a second facility, and Gurugram has further bed potential, creating a stated pathway toward approximately 2,000 beds by 2030. International patients represented 30% of Gurugram revenue in Q2 FY27 and approximately 27–30% of overall revenue, supported by patients from more than 150 countries. This is strategically important because medical-value travel, high-acuity case mix and premium realisations provide Artemis Medicare Services Limited with a differentiated revenue pool compared with hospitals focused primarily on domestic volumes. Consolidated H1 FY27 revenue rose 13.0% and PAT increased 22.2% year on year, while adjusted EBITDA grew 25.1% after excluding Raipur’s start-up losses. The underlying performance is therefore stronger than reported consolidated margins suggest, although the new hospital’s ramp-up, future capex and proposed fund raise remain important execution variables.

Over the past 52 weeks, Artemis Medicare Services Ltd has traded between a low of ₹202.85 and a high of ₹378.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Artemis Medicare Services Ltd has a market capitalization of approximately 4,516.48. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Artemis Medicare Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.26 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,516.48 Cr, Artemis Medicare Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Artemis Medicare Services Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Artemis Medicare Services Ltd is 39.26. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

International patients supplied 30% of Artemis Gurugram revenue in Q2 FY27. The share was 27% in Q1 FY27 and 32% in Q2 FY26.

Artemis reported an EBITDA margin of 23.8% in Q2 FY 27. That was 141 basis points above the 22.4% reported in Q2 FY 26 and 170 basis points above Q1 FY 27's 22.1%.

Artemis targets roughly 2,000 beds by 2030. Its roadmap shows about 1,000 beds in 2026 and identifies about 900 further pipeline beds from VIMHANS and Gurugram. A separate business-overview slide refers to about 2,000 beds by 2029.

Artemis Shanti created an implied Rs 8.61 crore difference between reported and adjusted consolidated EBITDA in Q2 FY27. Reported EBITDA was Rs 62.89 crore, compared with adjusted EBITDA of Rs 71.50 crore. The presentation says the adjusted measure excludes the Raipur unit’s revenue and EBITDA losses.